Treating COPD Comorbidities: A Market Opportunity for Systemic Anti-Inflammatory Agents?Decision ResourcesMarch 18, 2008 42 Pages - SKU: DECR1725835 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Summary
GBI Research, the leading
|
more...
|
$3,500.00
|
|
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider, has released its latest research
|
more...
|
$3,500.00
|
|
Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2012 Q2 Release]
4/16/2012 | published by: Supplier Relations US, LLC
This latest Biological Product (except Diagnostic) Manufacturing Industry report provides the most updated market research on the industry. Its scope contains analysis on the industry's key financial data, competitive landscape, shipment and inventory data,
|
more...
|
$599.00
|
|
Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012 provides data on the Viral Respiratory Tract Infection clinical trial scenario. This
|
more...
|
$1,000.00
|
|
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 provides data on the Bronchopulmonary Dysplasia clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
|
Lung Injury Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Lung Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H1, 2012 provides data on the Lung Injury clinical trial scenario. This report provides elemental information and data
|
more...
|
$1,000.00
|
Related Markets
Respiratory/Pulmonary Reports
- Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
- Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
- Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012
